1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

UK Prices Continue To Shoot Up In June

Pricewatch UK – June 2024

 
• By Dave Wallace

The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.

Price Watch UK
• Source: Alamy

June 2024 brought another month in which significant price increases were seen for a plethora of different generics in the UK, according to the latest figures from market researcher WaveData.

Based on pricing data to UK independent pharmacists, WaveData found that many generics saw their average trade

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Governor Newsom Expands Discounted Naloxone Availability To All Californians

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By Dave Wallace

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

More from Market Intelligence

UK Gabapentin Prices Shoot Up In December

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

UK Memantine Prices Spike In November

 
• By Dave Wallace

Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.

Apixaban Prices Begin To Correct After Months Of UK Rises

 
• By Dave Wallace

After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.